Thomas Dolca, CMO at Principia Biopharma, holds 0.00 shares in Chinook Therapeutics (Ticker: KDNY), holds 0.00 shares in Principia Biopharma (Ticker: PRNB), holds ― shares in Equillium (Ticker: EQ).

See the Hottest Stocks Based on Insider Trading >

Thomas Dolca
Principia Biopharma (PRNB)
CMO

Not Ranked

Thomas Dolca has not reported sufficient informative transactions and therefore cannot be ranked.

Time Frame

1 Year

Compare to

No Benchmark

How are Insiders Ranked?

Insider Holdings

Thomas Dolca does not currently own shares as a corporate insider.

A breakdown of Thomas Dolca's holdings

See the Top Stocks by Insiders

Insider Roles

Equillium
(EQ)

Chief Medical Officer

Allakos
(ALLK)

Director

Roles that Thomas Dolca holds in companies

See the Top Corporate Insiders

Most Profitable Insider Trade

Stock:

Chinook Therapeutics
(KDNY)

Rating:Informative Buy

Date:Sep 06, 2022 - Sep 06, 2023

Return:+98.40%

The most profitable trade made by Thomas Dolca

See the Latest Stocks Traded by Insiders

Thomas Dolca's Trading History

PRNB

Principia Biopharma

Sep 28, 2020

―

Uninformative Sell

220.70K

$0.00

KDNY

Chinook Therapeutics

Aug 11, 2023

―

Uninformative Sell

―

$0.00

Equillium

―

Chief Medical Officer

―

ALLK

Allakos

―

Director

―

List of latest transactions for each holding click on a transaction to see Thomas Dolca's performance on stock

See All Insider Trading from Today

Thomas Dolca insider profile FAQ

What is the percentage of profitable transactions made by Thomas Dolca?

The percentage of profitable transactions made by Thomas Dolca is ―.

What is the average return per transaction made by Thomas Dolca?

The average return per transaction made by Thomas Dolca is ―.

What stocks does Thomas Dolca hold?

Thomas Dolca holds: PRNB, KDNY, EQ, ALLK stocks.

What was Thomas Dolca’s latest transaction?

Thomas Dolca latest transaction was an Uninformative Sell of ―.

What was Thomas Dolca's most profitable transaction?

Thomas Dolca’s most profitable transaction was an Informative Buy of KDNY stock on September 6, 2022. The return on the trade was 98.40%.

What is Thomas Dolca's role in Principia Biopharma?

Thomas Dolca's role in Principia Biopharma is CMO.

How can I follow the stock ratings of top corporate insiders?

Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.

Thomas Dolca Insider Profile

Thomas Dolca Principia Biopharma (PRNB)CMO